Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany.
Klinik für Strahlentherapie und Radioonkologie, Franziskus Hospital, Kiskerstraße 26, 33615, Bielefeld, Germany.
J Cancer Res Clin Oncol. 2019 Mar;145(3):695-707. doi: 10.1007/s00432-018-02837-4. Epub 2019 Jan 23.
Mistletoe treatment of cancer patients is discussed highly controversial in the scientific literature. Aim of this systematic review is to give an extensive overview about current state of research concerning mistletoe therapy of oncologic patients regarding survival, quality of life and safety.
In September and October 2017 Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), PsycINFO, CINAHL and "Science Citation Index Expanded" (Web of Science) were systematically searched.
The search strategy identified 3647 hits and 28 publications with 2639 patients were finally included in this review. Mistletoe was used in bladder cancer, breast cancer, other gynecological cancers (cervical cancer, corpus uteri cancer, and ovarian cancer), colorectal cancer, other gastrointestinal cancer (gastric cancer and pancreatic cancer), glioma, head and neck cancer, lung cancer, melanoma and osteosarcoma. In nearly all studies, mistletoe was added to a conventional therapy. Patient relevant endpoints were overall survival (14 studies, n = 1054), progression- or disease-free survival or tumor response (10 studies, n = 1091). Most studies did not show any effect of mistletoe on survival. Especially high quality studies do not show any benefit.
With respect to survival, a thorough review of the literature does not provide any indication to prescribe mistletoe to patients with cancer.
在科学文献中，槲寄生治疗癌症患者的问题存在很大争议。本系统评价的目的是广泛概述关于槲寄生治疗肿瘤患者的生存、生活质量和安全性的当前研究现状。
2017 年 9 月至 10 月，系统检索了 Medline、Embase、Cochrane 中央对照试验注册库（CENTRAL）、PsycINFO、CINAHL 和“Science Citation Index Expanded”（Web of Science）。
搜索策略确定了 3647 个命中结果，最终纳入了 28 篇文献和 2639 例患者。槲寄生被用于膀胱癌、乳腺癌、其他妇科癌症（宫颈癌、子宫体癌和卵巢癌）、结直肠癌、其他胃肠道癌症（胃癌和胰腺癌）、脑胶质瘤、头颈部癌症、肺癌、黑色素瘤和骨肉瘤。在几乎所有的研究中，槲寄生都被添加到常规治疗中。与患者相关的终点包括总生存（14 项研究，n=1054）、无进展或疾病生存或肿瘤反应（10 项研究，n=1091）。大多数研究没有显示槲寄生对生存有任何影响。特别是高质量的研究没有显示任何益处。
就生存而言，对文献的全面回顾并没有提供任何给癌症患者开槲寄生的依据。
